March 9th, 2015
This week’s topics include the effects of low BP in cognitively impaired elderly patients taking antihypertensive drugs and the effects of blood-pressure lowering on CV risk according to baseline BMI.
January 22nd, 2015
A novel implantable device appears to show early promise in the treatment of resistant hypertension. The “Coupler” device from ROX Medical is about the size of a paper clip and is delivered via a catheter to the upper thigh, where it creates an anastomosis between the distal external iliac vein and artery, thereby mechanically lowering […]
September 30th, 2013
This week’s topics include the RE-ALIGN trial of dabigatran vs. warfarin in patients with mechanical heart valves, general population echo screening and long-term survival, and antihypertensives and breast cancer risk among middle aged women.
August 29th, 2013
A Chief Resident surveys the rapidly changing landscape of hypertension management.
February 2nd, 2013
The 2009 report of the Kyoto Heart Study on the add-on effect of valsartan in hypertension has been retracted with a terse comment by the editors of the European Heart Journal.
September 25th, 2012
Although the patent on valsartan (Diovan, Novartis) expired last Friday, a generic version of the popular antihypertensive drug has yet to make it to market. By contrast, a generic version of Diovan HCT, the combination of valsartan and hydrochlorothiazide, was recently launched by generic drug maker Mylan. As reported on Pharmalot, Ranbaxy, the embattled generic drug maker, holds the exclusive […]